Receptor Protein-Tyrosine Kinases, antagonists & inhibitors

Name
Receptor Protein-Tyrosine Kinases, antagonists & inhibitors
Accession Number
DBCAT001758
Description

Not Available

Drugs
DrugDrug Description
LinifanibInvestigated for use/treatment in leukemia (myeloid), myelodysplastic syndrome, and solid tumors.
CabozantinibA tyrosine kinase inhibitor used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer.
CeritinibAn antineoplastic kinase inhibitor used to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients with inadequate clinical response or intolerance to crizotinib.
FamitinibFamitinib has been used in trials studying the treatment of Colorectal Cancer, Renal Cell Cancer, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, and Metastatic Renal Cell Cancer, among others.
Drugs & Drug Targets
DrugTargetType
LinifanibReceptor-type tyrosine-protein kinase FLT3target
LinifanibVascular endothelial growth factor receptor 1target
LinifanibVascular endothelial growth factor receptor 2target
LinifanibVascular endothelial growth factor receptor 3target
LinifanibMast/stem cell growth factor receptor Kittarget
LinifanibMacrophage colony-stimulating factor 1 receptortarget
CabozantinibCytochrome P450 3A4enzyme
CabozantinibCytochrome P450 2C9enzyme
CabozantinibHepatocyte growth factor receptortarget
CabozantinibVascular endothelial growth factor receptor 2target
CabozantinibProto-oncogene tyrosine-protein kinase receptor Rettarget
CabozantinibCytochrome P450 2C8enzyme
CeritinibALK tyrosine kinase receptortarget
CeritinibP-glycoprotein 1transporter
CeritinibCytochrome P450 2C9enzyme
CeritinibCytochrome P450 3A4enzyme